Drugging RB1 Deficiency: Synthetic Lethality with Aurora Kinases.
Two recent reports describe pharmacologic approaches to specifically treat RB1-mutant cancers. The basis of this approach is a synthetic lethal relationship between RB1 mutations and inhibition of Aurora kinases A or B.See related article by Oser et al., p. 230.See related article by Gong et al., p. 248.